Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

Sarah E. M. Herman, Rosa Lapalombella, Amber L. Gordon, Asha Ramanunni, Kristie A. Blum, Jeffrey Jones, Xiaoli Zhang, Brian J. Lannutti, Kamal D. Puri, Natarajan Muthusamy, John C. Byrd, Amy J. Johnson

Blood (2011) 117 (16): 4323–4327.

https://doi.org/10.1182/blood-2010-11-315705

Published: 2011

Journal Articles

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Brian J. Lannutti, Sarah A. Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey W. Tyner, Marc M. Loriaux, Mike Deininger, Brian J. Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese

Blood (2011) 117 (2): 591–594.

https://doi.org/10.1182/blood-2010-03-275305

Published: 2011

Includes: Supplemental data

Journal Articles

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E. M. Herman, Amber L. Gordon, Amy J. Wagner, Nyla A. Heerema, Weiqiang Zhao, Joseph M. Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, Xiaoli Zhang, Lai Wei, John C. Byrd, Amy J. Johnson

Blood (2010) 116 (12): 2078–2088.

https://doi.org/10.1182/blood-2010-02-271171

Published: 2010

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

Journal Articles

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

Sarah E. May, Adam Kashishian, Thomas S. Lin, MD, PhD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Roger G. Ulrich, PhD, Hao Chen, PhD, Albert S. Yu, MD, PhD, Kamal D. Puri, PhD, BSc, MSc, Brian J. Lannutti, PhD, Neill A. Giese, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2008) 112 (11): 3165.

https://doi.org/10.1182/blood.V112.11.3165.3165

Published: 2008

Journal Articles

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

Hiroshi Ikeda, MD, PhD, Teru Hideshima, MD, PhD, Yutaka Okawa, MD, PhD, Sonia Vallet, MD, Samantha Pozzi, Loredana Santo, MD, Gullu Gorgun, Mariateresa Fulciniti, Noopur S. Raje, MD, Giulia Perrone, Nikhil Munshi, MD, Paul Richardson, MD, Brian J Lannutti, Kamal D. Puri, Neill A. Giese, Kenneth C. Anderson, MD

Blood (2008) 112 (11): 2753.

https://doi.org/10.1182/blood.V112.11.2753.2753

Published: 2008

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Brian J Lannutti, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Sarah May, Amy J. Johnson, Roger G. Ulrich, Albert Yu, Michael W. Gallatin, John C. Byrd, MD, Kamal D. Puri, Neill A. Giese

Blood (2008) 112 (11): 16.

https://doi.org/10.1182/blood.V112.11.16.16

Published: 2008

Journal Articles

Leukocyte PI3Kγ and PI3Kδ have temporally distinct roles for leukocyte recruitment in vivo

Lixin Liu, Kamal D. Puri, Josef M. Penninger, Paul Kubes

Blood (2007) 110 (4): 1191–1198.

https://doi.org/10.1182/blood-2006-11-060103

Published: 2007

Journal Articles

The role of endothelial PI3Kγ activity in neutrophil trafficking

Kamal D. Puri, Teresa A. Doggett, Ching-Yu Huang, Jason Douangpanya, Joel S. Hayflick, Martin Turner, Josef Penninger, Thomas G. Diacovo

Blood (2005) 106 (1): 150–157.

https://doi.org/10.1182/blood-2005-01-0023

Published: 2005

Journal Articles

Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue

Kamal D. Puri, Teresa A. Doggett, Jason Douangpanya, Yonghao Hou, William T. Tino, Tim Wilson, Thomas Graf, Elizabeth Clayton, Martin Turner, Joel S. Hayflick, Thomas G. Diacovo

Blood (2004) 103 (9): 3448–3456.

https://doi.org/10.1182/blood-2003-05-1667

Published: 2004

NARROW

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

PI3K/p110δ is a novel therapeutic target in multiple myeloma

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Leukocyte PI3Kγ and PI3Kδ have temporally distinct roles for leukocyte recruitment in vivo

The role of endothelial PI3Kγ activity in neutrophil trafficking

Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only